Nothing Special   »   [go: up one dir, main page]

MX2019009137A - Inhibicion de agregacion plaquetaria usando anticuerpos gpvi antihumanos. - Google Patents

Inhibicion de agregacion plaquetaria usando anticuerpos gpvi antihumanos.

Info

Publication number
MX2019009137A
MX2019009137A MX2019009137A MX2019009137A MX2019009137A MX 2019009137 A MX2019009137 A MX 2019009137A MX 2019009137 A MX2019009137 A MX 2019009137A MX 2019009137 A MX2019009137 A MX 2019009137A MX 2019009137 A MX2019009137 A MX 2019009137A
Authority
MX
Mexico
Prior art keywords
inhibition
platelet aggregation
human gpvi
gpvi antibodies
hours
Prior art date
Application number
MX2019009137A
Other languages
English (en)
Inventor
Jandrot-Perrus Martine
Billiald Philippe
Avenard Gilles
Original Assignee
Acticor Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acticor Biotech filed Critical Acticor Biotech
Publication of MX2019009137A publication Critical patent/MX2019009137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una proteína humanizada aislada que se une a la Glicoproteína VI humana (hGPVI) para tratar una afección relacionada con GPVI en un sujeto que la necesita, en donde dicha proteína humanizada aislada debe administrarse durante por lo menos 2 horas al sujeto, preferiblemente durante por lo menos 4 a 6 horas.
MX2019009137A 2017-02-03 2018-02-02 Inhibicion de agregacion plaquetaria usando anticuerpos gpvi antihumanos. MX2019009137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17154658 2017-02-03
PCT/EP2018/052664 WO2018141909A1 (en) 2017-02-03 2018-02-02 Inhibition of platelet aggregation using anti-human gpvi antibodies

Publications (1)

Publication Number Publication Date
MX2019009137A true MX2019009137A (es) 2019-12-19

Family

ID=57963133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009137A MX2019009137A (es) 2017-02-03 2018-02-02 Inhibicion de agregacion plaquetaria usando anticuerpos gpvi antihumanos.

Country Status (15)

Country Link
US (2) US11692033B2 (es)
EP (1) EP3577136A1 (es)
JP (2) JP7360945B2 (es)
KR (2) KR20240046168A (es)
CN (1) CN110494447B (es)
AU (2) AU2018214222C1 (es)
BR (1) BR112019016065A8 (es)
CA (1) CA3051169A1 (es)
IL (1) IL268299B2 (es)
MA (1) MA47415A (es)
MX (1) MX2019009137A (es)
NZ (1) NZ755339A (es)
SG (1) SG11201906530TA (es)
TW (2) TW202339799A (es)
WO (1) WO2018141909A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250026A1 (en) * 2020-06-08 2021-12-16 Acticor Biotech Use of anti-gpvi antibodies for the treatment of acute respiratory distress syndrome
EP4399228A1 (en) * 2021-09-07 2024-07-17 Etablissement Français du Sang Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
WO2023156683A1 (en) * 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
IE69054B1 (en) 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
DE3903581A1 (de) 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
WO1993024635A1 (en) 1992-06-03 1993-12-09 Genentech, Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1406929A2 (en) 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
GB0511590D0 (en) 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
US7611707B2 (en) 2004-04-29 2009-11-03 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods thereof
EP1876240B1 (en) 2005-04-28 2012-08-22 Mochida Pharmaceutical Co., Ltd. Anti-human platelet membrane glycoprotein vi monoclonal antibody
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1916259A1 (en) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
KR20120102125A (ko) * 2009-12-18 2012-09-17 사노피 Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도
RU2619180C2 (ru) 2011-09-01 2017-05-12 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Антитела к xcr1 человека
JP6251677B2 (ja) 2011-09-08 2017-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新規の突然変異組織プラスミノーゲン活性化因子及びその使用
CN108289939B (zh) * 2015-08-05 2022-08-12 艾科迪科尔生物技术公司 抗人gpvi抗体及其用途

Also Published As

Publication number Publication date
KR20190121767A (ko) 2019-10-28
CN110494447B (zh) 2024-06-04
TWI810173B (zh) 2023-08-01
TW202339799A (zh) 2023-10-16
US20230391869A1 (en) 2023-12-07
BR112019016065A2 (pt) 2020-05-26
NZ755339A (en) 2024-07-05
US20190367608A1 (en) 2019-12-05
RU2019127768A3 (es) 2021-05-28
IL268299B2 (en) 2024-10-01
AU2021202612B2 (en) 2024-03-14
KR102633644B1 (ko) 2024-02-05
AU2018214222C1 (en) 2021-08-05
MA47415A (fr) 2019-12-11
AU2021202612A1 (en) 2021-05-27
US11692033B2 (en) 2023-07-04
SG11201906530TA (en) 2019-08-27
WO2018141909A1 (en) 2018-08-09
KR20240046168A (ko) 2024-04-08
RU2019127768A (ru) 2021-03-03
JP2023109987A (ja) 2023-08-08
JP7360945B2 (ja) 2023-10-13
CN110494447A (zh) 2019-11-22
TW201839009A (zh) 2018-11-01
AU2018214222B2 (en) 2021-01-28
IL268299B1 (en) 2024-06-01
BR112019016065A8 (pt) 2022-10-18
CA3051169A1 (en) 2018-08-09
AU2018214222A1 (en) 2019-08-01
EP3577136A1 (en) 2019-12-11
JP2020507317A (ja) 2020-03-12
IL268299A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
MX2023000334A (es) Anticuerpos anti-trem2 y metodos de uso de los mismos.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MY193249A (en) Anti-human cd19 antibodies with high affinity
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
SG10201801219VA (en) Anti-HER2 Antibodies
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
NZ755339A (en) Inhibition of platelet aggregation using anti-human gpvi antibodies
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
PH12019502694A1 (en) Anti-trkb antibodies
RU2017135005A (ru) Фармацевтическая композиция для лечения и/или предотвращения злокачественной опухоли
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
SA521431223B1 (ar) Angpt2 أجسام مضادة لـ
MX2022003523A (es) Proteinas de union a antigenos.
IL288474A (en) Anti-TNF antibodies, preparations and methods for the treatment of active ankylosing spondylitis
WO2021058795A3 (en) Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
MX2016011228A (es) Anticuerpos biespecificos novedosos de union a tlr2 humano y tlr4 humano.